Heart risk reduction in prostate cancer patients on hormone therapy
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether a team of doctors, nurses, and other specialists can help reduce the risk of heart problems in men with prostate cancer who are on hormone therapy (ADT). It focuses on providing extra support for heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 80 years old.
- You have been diagnosed with prostate cancer (by biopsy or clinical signs).
- You plan to receive hormone therapy (ADT) for at least one year.
- You have not had a heart attack, stroke, or serious leg artery disease in the past year.
- You have not had hormone therapy for prostate cancer in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at heart health in men with prostate cancer who are taking or will take hormone therapy (ADT) for at least 6 months. It aims to learn more about cardiovascular risks and how to manage them.
This study checks how men starting hormone therapy (ADT) for prostate cancer are doing with their heart health. It offers follow-up visits at the cancer center to track blood pressure and lab results, with the goal of catching any heart-related issues early.
This study tests whether a supervised exercise program can help reduce heart disease risk in men with prostate cancer who are on hormone therapy. Participants will exercise at home or in a group and be monitored for heart health changes.
This study looks at how a special CT heart scan (CCTA) can help manage heart disease risk in men with prostate cancer who are taking hormone therapy (ADT). It may help your care team better assess heart risk, especially if you also have other heart risk factors but no current heart symptoms.
This study tests whether a supervised exercise program can help men with prostate cancer stay stronger and feel better during combined radiation and hormone therapy. You may be able to join if you are about to start these treatments and are otherwise healthy enough to exercise.
This study looks at heart-related risks in older men with advanced prostate cancer who are taking enzalutamide or darolutamide. It may help doctors better understand how to manage heart health during treatment.
Hear when a new Cardiovascular Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.